Abstract:First discovered in Wuhan, China, SARS-CoV-2 is a highly pathogenic novel coronavirus, which rapidly spread globally and became a pandemic with no vaccine and limited distinctive clinical drugs available till March 13th, 2020. Ribonucleic Acid interference (RNAi) technology, a gene-silencing technology that targets mRNA, can cause damage to RNA viruses effectively. Here, we report a new efficient small interfering RNA (siRNA) design method named Simple Multiple Rules Intelligent Method (SMRI) to propose a new solution of the treatment of COVID-19. To be specific, this study proposes a new model named Base Preference and Thermodynamic Characteristic model (BPTC model) indicating the siRNA silencing efficiency and a new index named siRNA Extended Rules index (SER index) based on the BPTC model to screen high-efficiency siRNAs and filter out the siRNAs that are difficult to take effect or synthesize as a part of the SMRI method, which is more robust and efficient than the traditional statistical indicators under the same circumstances. Besides, to silence the spike protein of SARS-CoV-2 to invade cells, this study further puts forward the SMRI method to search candidate high-efficiency siRNAs on SARS-CoV-2's S gene. This study is one of the early studies applying RNAi therapy to the COVID-19 treatment. According to the analysis, the average value of predicted interference efficiency of the candidate siRNAs designed by the SMRI method is comparable to that of the mainstream siRNA design algorithms. Moreover, the SMRI method ensures that the designed siRNAs have more than three base mismatches with human genes, thus avoiding silencing normal human genes. This is not considered by other mainstream methods, thereby the five candidate high-efficiency siRNAs which are easy to take effect or synthesize and much safer for human body are obtained by our SMRI method, which provide a new safer, small dosage and long efficacy solution for the treatment of COVID-19. Supplementary information: The online version contains supplementary material available at 10.1007/s11390-021-0826-x.

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference.

Inhibition of Severe Acute Respiratory Syndrome Virus Replication by Small Interfering RNAs in Mammalian Cells

Therapeutic and Prophylactic Potential of Small Interfering RNAs Against Severe Acute Respiratory Syndrome

Inhibition Of Sars-Cov Gene Expression By Adenovirus-Delivered Small Hairpin Rna

Small Interfering Rna Inhibits Sars-Cov Nucleocapsid Gene Expression in Cultured Cells and Mouse Muscles

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

An Effective Platform for SARS-CoV-2 Prevention by Combining Neutralization and RNAi Technology

siRNA targeting the Leader sequence of SARS-CoV inhibits virus replication

A coronavirus-mimic mesoporous silica nanosystem enables efficient targeted delivery of siRNA for anti-SARS-CoV‐2

RNAi Therapeutics: Can Sirnas Conquer SARS?

Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

Inhibition of SARS-CoV Infection in Vero-E6 Cells by Sirnas

Inhibition of Gene Expression Directed by Small Interfering Rnas in Infectious Bronchitis Virus

Cellular Micrornas Target SARS-CoV-2 Spike Protein and Restrict Viral Replication

Properties of Isonucleotide-Incorporated Oligodeoxynucleotides and Inhibition of the Expression of Spike Protein of Sars-Cov

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

SMRI: A New Method for siRNA Design for COVID-19 Therapy

Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein

Virus-specific Dicer-substrate siRNA swarms inhibit SARS-CoV-2 infection in TMPRSS2-expressing Vero E6 cells